2015 American Transplant Congress
Differential Clinical Outcomes in Kidney Transplant Recipients With De Novo C1q+ and C1q- Donor Specific Antibodies
Background: We investigated the prevalence and clinical significance of C1q binding versus non-C1q binding de novo DSA in kidney transplant recipients.Methods: The study group included…2015 American Transplant Congress
Rituximab With Intravenous Immune Globulin in Sensitized Patients Awaiting Heart Transplant: Does It Work?
Cedars-Sinai Heart Institute, Los Angeles, CA.
Purpose: Highly sensitized heart transplant (HTx) recipients with donor specific antibodies (DSA) are at increased risk of rejection and death. Rituximab with Intravenous Immune Globulin…2015 American Transplant Congress
Costimulation Blockade and Bortezomib to Desensitize Rhesus Macaque and Prolong Renal Allograft Survival
Surgery, Emory Transplant Center, Atlanta, GA.
[Background] Preformed donor specific antibody (DSA) due to prior sensitization affects a significant population of transplant patients, portending a poorer prognosis in short- and long-term…2015 American Transplant Congress
Anti-Thymocyte Globulin Induction in Infected Mechanical Circulatory Support Patients: Is It Safe?
Cedars-Sinai Heart Institute, Los Angeles, CA.
Purpose: The use of mechanical circulatory assist devices (MCSD) have been increasing over the past several years. Driveline infections (DLI) are one of the most…2015 American Transplant Congress
A Prospective Pilot Study Evaluating the Safety and Efficacy of Everolimus for the Prevention of CMV and BK Viral Infection (BKV) in Broadly Sensitized Kidney Transplant Recipients Following Desensitization With IVIG and Rituximab: Interim Analysis
Introduction: Everolimus, a second generation mTOR inhibitor, may prevent CMV and BKV infection after kidney transplantation. Broadly sensitized patients are at greater risk of viral…2015 American Transplant Congress
Outcomes of Simultaneous Pancreas and Kidney Transplantation With a High Level of Preformed Antibodies
Transplant Surgery, Manchester Royal Infirmary, Manchester, United Kingdom.
BACKGROUND:There is paucity of data of outcomes of simultaneous pancreas and kidney transplantation in recipients with preformed antibodies. Newer induction agents have been used with…2015 American Transplant Congress
Does the C1q Assay Predict the Result of Lymphocyte Flow Cross-Match (FCxM) in Potential Renal Transplant Recipients With HLA-DSA and AHG-CDC CxM negative?
Background. The presence of pre-transplant HLA donor specific antibodies (DSA) is a recognized risk factor for acute rejection. However, due to the test's (LUMINEX) high…2015 American Transplant Congress
Blocking CD4 T Cell Helper Functions Improves Efficacy of ATG Treatment in Sensitized Transplant Recipients
Immunology, Cleveland Clinic, Cleveland, OH.
Antibody mediated lymphocyte depletion is used in clinical transplantation to improve graft function. While the presence of donor-reactive memory T cells is the primary rationale…2015 American Transplant Congress
Impact of HLA Antibody Monitoring After Kidney Transplantation
The impact of donor specific antibodies (DSA) and optimal therapeutic intervention for DSA in kidney transplant (KT) recipients has been reported with variable results. We…2015 American Transplant Congress
The Use of Bortezomib for Desensitization in ABO Incompatible and Positive Crossmatch Kidney Transplant
Introduction:ABO incompatible (ABOi) and positive crossmatch (PXM) living donor kidney transplantation is a life-saving alternative to dialysis. A variety of protocols exist utilizing plasmapheresis (PP)…
American Transplant Congress abstracts